Amgen Inc
Change company Symbol lookup
Select an option...
AMGN Amgen Inc
ADI Analog Devices Inc
BAC Bank of America Corp
CLOV Clover Health Investments Corp
HRL Hormel Foods Corp
DD Dupont De Nemours Inc
PSRU Valiant Eagle Inc
CRM Salesforce.Com Inc
VLYPP Valley National Bancorp
FEMKX Fidelity® Emerging Markets Fund
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Postmarket

Last Trade
Delayed
$226.25
0.56 (0.25%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$225.69
Day's Change
-1.35 (-0.59%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
227.89
Day's Low
225.28
Volume
(Average)
Volume:
2,407,586

10-day average volume:
2,435,602
2,407,586

Company Profile

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Valuation Ratios

Price/Earnings (TTM)
18.44x
Price/Sales (TTM)
5.16x
Price/Book (MRQ)
13.95x
Price/Cash Flow (TTM)
12.07x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend

Short Interest

February 2021
Current Month
8.7M
Previous Month
7.6M
Percent of Float
1.51%
Days to Cover
3.7853 Days

Share Information

AMGN is in a share class of common stock
Float
576.5M
Shares Outstanding
577.6M
Institutions Holding Shares
2,761
73.74%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Robert A. BradwayChmn.
  • Peter H. GriffithCFO
  • Murdo GordonExec.VP
  • David M. ReeseExec.VP
  • Esteban SantosExec.VP

Address

  • 1 Amgen Center Dr
  • Thousand Oaks, CA 91320-1730
  • Phone: (805) 447-1000
  • Fax: (805) 447-1010
  • http://www.amgen.com

Insider Trading

During the most recent quarter, 14K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.